ABBV AbbVie Inc. Common Stock
O AbbVie Inc. Common Stock Przegląd firmy z Wikipedii
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
Czytaj więcej
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.
History
AbbVie was formed in 2012 as a corporate spin-off from Abbott Laboratories. It became a public company in January 2013.
In January 2014, the company acquired ImmuVen, a startup incubated at the University of Illinois Urbana-Champaign and focused on biotherapeutics to treat cancer, infectious disease, and autoimmune disorders.
In September 2014, AbbVie and Infinity Pharmaceuticals entered into a collaboration to develop and commercialize duvelisib, Infinity's PI3K inhibitor for the treatment of patients with cancer. On the same day, AbbVie and Calico entered into a research and development (R&D) collaboration intended to discover, develop and bring to market new therapies for patients with aging-associated diseases including neurodegeneration and cancer. California Life Company, operating as Calico, is an Alphabet Inc. subsidiary focused on aging and age-related diseases, and led by former Genentech chairman and CEO of Arthur D. Levinson and former Genentech EVP and chief medical officer Hal V. Barron (who subsequently left the company).
In October 2014, AbbVie ended its efforts to acquire Shire, which would have been one of the largest mergers and acquisitions (M&A) deals of that year and one of the largest tax inversions in history, due to changes in the US tax code by the US Treasury; AbbVie had to pay a $1.6 billion breakup fee.
In May 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers, ibrutinib; AstraZeneca had also been bidding to acquire Pharmacyclics. The Pharmacyclics name was retained, and it operated as a subsidiary of AbbVie from its previous Sunnyvale, California headquarters until the consolidation of AbbVie Bay Area sites in a new building in South San Francisco. In June 2015, AbbVie and Halozyme Therapeutics entered into a global collaboration and licensing agreement to develop and commercialize products that combine AbbVie's treatments and Halozyme's ENHANZE drug-delivery technology, this was terminated in November 2016.
In February 2016, AbbVie and Cambridge, Massachusetts-based Synlogic announced a multi-year R&D collaboration. Synlogic is a synthetic biology company built on research from the labs of James Collins and Tim Lu at MIT. As part of the collaboration, AbbVie is getting worldwide rights to Synlogic's probiotic-based technology for treating inflammatory bowel disease, and the research teams will focus on Crohn's disease and ulcerative colitis.
In April 2016, the company announced it would acquire Stemcentrx for up to $9.8 billion. A day later, the company announced an expansion of a two and a half-year-old cystic fibrosis deal with Galapagos NV, potentially doubling milestone payments to $600 million.
Also in April 2016, the company partnered with the University of Chicago to investigate several areas of oncology: breast, lung, prostate, colorectal and hematological cancers.
Also in April 2016, the company announced it would co-commercialize Argenx's preclinical immunotherapy, ARGX-115. ARGX-115 is a first-in-class immunotherapy targeting GARP (glycoprotein A repetitions predominant), a membrane protein believed to enhance the immunosuppressive effects of T cells. The company also announced a deal to co-develop/commercialize at least one of CytomX Probody's conjugates against CD71 (transferrin receptor 1).
In June 2019, AbbVie announced it would acquire Irish-based Allergan plc for about $63 billion; however the transaction was not structured as a tax inversion; AbbVie remained legally domiciled in the U.S. for tax purposes. To gain FTC approval, the company divested Allergan's late-stage gastrointestinal candidate brazikumab to AstraZeneca as well as two pancreatic replacement enzymes, Zenpep and Viokace, to Nestlé. In July 2019, the company announced it would acquire Mavupharma, boosting its cancer drug pipeline.
In March 2020, during the COVID-19 pandemic, AbbVie announced plans to evaluate the Kaletra/Aluvia HIV medicine as possible COVID-19 treatment. The company entered into various partnerships with health authorities in different countries to investigate the efficacy of the medication. However, the first non-blinded, randomized trial found the drug not useful to treat severe COVID-19. The Israeli government announced that it would force AbbVie to license its patents for Kaletra, the brand name of lopinavir/ritonavir, a fixed dose combination medication for the treatment and prevention of HIV/AIDS which was also thought to have some applicability to fighting COVID-19. In response, AbbVie announced that it would cease enforcing its patents on the drug entirely.
In May 2021, Allergan Aesthetics announced the acquisition of Soliton. In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma.
In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118. In October, the company acquired DJS Antibodies for $225 million, giving it access to an experimental drug for an aggressive lung disease as well as technology to develop certain antibody medicines. In January 2023, Humira began facing competition from biosimilars.
In February 2024, AbbVie acquired ImmunoGen for $10.1 billion, aiming to expedite its entry into the ovarian cancer treatment market with ImmunoGen's drug Elahere. In the same month, AbbVie and Tentarix Biotherapeutics announced the beginning of a long-term collaboration in the discovery and development of opportunistic, multi-specific biological candidates in oncology and immunology. AbbVie provides expertise in these areas, and will also provide Tentarix with option advances worth $64 million for two programs, and Tentarix will provide its patented Tentarix Tentacles™platform. AbbVie also received an option to purchase the software in full.
In March 2024, the company announced it would acquire Landos Biopharma for over $200 million. In June 2024, Robert Michael replaced Richard Gonzalez as CEO of AbbVie. Gonzalez became the executive chairman. In August 2024, AbbVie acquired neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an attempt to expand its drug pipeline. In September 2024, AbbVie filed a lawsuit against BeiGene accusing it of stealing trade secrets to develop a competing therapy to treat blood and bone marrow cancers related to the growth of "B cells" after BeiGene hired a former longtime senior AbbVie scientist. In October 2024, AbbVie acquired Aliada Therapeutics for $1.4 billion to expand its neuroscience pipeline.
In January 2025, AbbVie acquired Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune area, for $200 million. In the same month, AbbVie announced a $1.64 billion partnership with Neomorph to develop new molecular glue degraders for multiple targets across oncology and immunology, as well as a $1 billion partnership with Simcere Zaiming to develop an investigational drug candidate for multiple myeloma. In May 2025, AbbVie entered into a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology, and oncology. In August 2025, AbbVie acquired Bretisilocin, which is under development for the treatment of major depressive disorder, from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
In January 2026, AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over the next 10 years and lower Medicaid prices. In exchange, the administration exempted AbbVie from tariffs and future pricing mandates.
Acquisition history
Major products
The company's major products are: Humira (adalimumab) ($9 billion in 2024 revenues, 16% of total revenues), approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease and ulcerative colitis and administered via injection; Skyrizi (Risankizumab) ($11.7 billion in 2024 revenues, 21% of total revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases; Rinvoq (Upadacitinib) ($6.0 billion in 2023 revenues, 11% of total revenues), used to treat arthritis; and Botox ($6.0 billion in 2024 revenues, 11% of total revenues). Its other major products include Imbruvica (Ibrutinib) to treat cancer ($3.3 billion in 2024 revenues), Vraylar (Cariprazine) to treat schizophrenia and bipolar disorder ($3.3 billion in 2024 revenues), Venclexta (Venetoclax) to treat leukemia and lymphoma ($2.6 billion in 2024 revenues), Mavyret (Glecaprevir/pibrentasvir) to treat Hepatitis C ($1.3 billion in 2024 revenues), and Epkinly (epcoritamab), a blood-cancer therapy developed in partnership with Genmab ($0.1 billion in 2024 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev (Foscarbidopa/foslevodopa) and tavapadon.
Legal issues
Anti-competitive practices
AbbVie has been accused of using anti-competitive patent thickets to prevent potentially cheaper biosimilars from entering the market. AbbVie and Alvotech, filed lawsuits against each other regarding a Humira biosimilar introduced by Alvotech. The lawsuits were settled out of court in 2022. Forest Laboratories, a subsidiary of AbbVie, was accused of using unlawful deals to prevent generic versions of its Alzheimer's disease drug, Namenda, from entering the market. In 2018, AbbVie agreed to pay $25 million to resolve allegations that it used kickback schemes to promote its cholesterol drug TriCor (fenofibrate). In 2020, AbbVie agreed to pay $24 million to resolve allegations that it used kickback schemes to promote Humira using "nurse ambassadors".
A report from the House Oversight and Reform Committee found that "AbbVie pursued a variety of tactics to increase drug sales while raising prices for Americans, including exploiting the patent system to extend its market monopoly, abusing orphan drug protections to further block competition, and engaging in anticompetitive pricing practices". Pursuant to the Inflation Reduction Act, the price of Imbruvica was reduced by 38%, to $9,319 per month, effective in 2026.
Tax avoidance
In June 2021, the United States Senate Finance Committee, under Chair Ron Wyden (D-OR), began an investigation to determine if the company took advantage of loopholes in the Tax Cuts and Jobs Act of 2017 to significantly reduce its tax liability. In a letter to AbbVie CEO Richard Gonzalez, Wyden noted the company suffered a 2020 pretax loss in the US of $4.5 billion and an overseas pretax profit of $7.9 billion the same year. The report, released in July 2022, showed that AbbVie was able to dodge U.S. taxes by registering intellectual property in offshore jurisdictions such as Bermuda. As a result, while AbbVie received 75% of its sales of Humira in the United States, it only reported 1% of that income for U.S. tax purposes.
Marketing of opioid painkillers
In July 2022 the company agreed to pay up to $2.37 billion to settle U.S. lawsuits against its Allergan unit over the marketing of opioid analgesics. AbbVie denied any wrongdoing.
Litigation by the company against the NHS
In 2018, AbbVie sued NHS England in the Technology and Construction Court claiming that the agency breached procurement rules and had not treated the company fairly when seeking suppliers for hepatitis C treatments. In 2019, a UK court dismissed AbbVie's case against the NHS.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
ABBV Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
ABBV Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
| Data ex-dywidendy | Kwota |
|---|---|
| 15 lipca 2026 | $1,7300 |
| 15 kwietnia 2026 | $1,7300 |
| 16 stycznia 2026 | $1,7300 |
| 15 października 2025 | $1,6400 |
| 15 lipca 2025 | $1,6400 |
| 15 kwietnia 2025 | $1,6400 |
| 15 stycznia 2025 | $1,6400 |
| 15 października 2024 | $1,5500 |
| 15 lipca 2024 | $1,5500 |
| 12 kwietnia 2024 | $1,5500 |
| 12 stycznia 2024 | $1,5500 |
| 12 października 2023 | $1,4800 |
| 13 lipca 2023 | $1,4800 |
| 13 kwietnia 2023 | $1,4800 |
| 12 stycznia 2023 | $1,4800 |
| 13 października 2022 | $1,4100 |
| 14 lipca 2022 | $1,4100 |
| 13 kwietnia 2022 | $1,4100 |
| 13 stycznia 2022 | $1,4100 |
| 14 października 2021 | $1,3000 |
ABBV Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
- Mocne kupno 9 23,7%
- Kup 22 57,9%
- Trzymaj 7 18,4%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
29 analityków · 2026-08-18Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $3.65 | $3.68 | -0.03% |
| 31 marca 2026 | $2.65 | $2.65 | 0.00% |
| 31 grudnia 2025 | $2.71 | $2.71 | 0.00% |
| 30 września 2025 | $1.86 | $1.81 | 0.05% |
| 30 czerwca 2025 | $2.97 | $2.94 | 0.03% |
| 31 marca 2025 | $2.46 | $2.43 | 0.03% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| ABBV | — | 96.8 | 8.6% | 6.9% | 15367.3% | — |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | — |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 15
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Cost of Revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B | $7.04B | $5.83B | $4.50B | $4.43B | |
| SG&A Expense | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B | $7.40B | $6.29B | $5.88B | $6.39B | $7.72B | |
| Operating Expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B | $18.67B | $16.30B | $15.32B | $16.55B | |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B | $7.54B | $3.41B | |
| Interest Expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B | $1.15B | $1.05B | $719M | $429M | |
| Other Non-op | $-5.79B | $-3.24B | $-4.68B | $-2.45B | $-2.50B | $-5.61B | $-3.01B | $-18M | $-466M | $-188M | $-13M | $27M | |
| Pretax Income | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B | $7.73B | $7.88B | $6.64B | $2.37B | |
| Income Tax | $2.36B | $-570M | $1.38B | $1.63B | $1.44B | $-1.22B | $544M | $-490M | $2.42B | $1.93B | $1.50B | $595M | |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| EPS (Basic) | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 | $3.31 | $3.65 | $3.15 | $1.11 | |
| EPS (Diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | |
| Shares (Basic) | 1,769,000,000 | 1,769,000,000 | 1,768,000,000 | 1,771,000,000 | 1,770,000,000 | 1,667,000,000 | 1,481,000,000 | 1,541,000,000 | 1,596,000,000 | 1,622,000,000 | 1,625,000,000 | 1,595,000,000 | |
| Shares (Diluted) | 1,773,000,000 | 1,773,000,000 | 1,773,000,000 | 1,778,000,000 | 1,777,000,000 | 1,673,000,000 | 1,484,000,000 | 1,546,000,000 | 1,603,000,000 | 1,631,000,000 | 1,637,000,000 | 1,610,000,000 | |
| EBITDA | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.59B | $9.38B | $7.54B | $3.41B |
Bilans 26
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B | $9.30B | $5.10B | $8.40B | $8.35B | |
| Short-term Investments | $28M | $31M | $2M | $28M | $84M | $30M | $0 | $772M | $486M | $1.32B | $8M | $26M | |
| Receivables | $12.59B | $10.92B | $11.15B | $11.25B | $9.98B | $8.82B | $5.43B | $5.38B | $5.09B | $4.76B | $4.73B | · | |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | $3.13B | $3.31B | $1.81B | $1.60B | $1.60B | $1.44B | $1.72B | $1.12B | |
| Prepaid Expense | $6.29B | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B | $16.95B | $21.22B | $16.19B | $16.31B | $16.08B | |
| PP&E (Net) | $5.63B | $5.13B | $4.99B | $4.93B | $5.11B | $5.25B | $2.96B | $2.88B | $2.80B | $2.60B | $2.56B | $2.48B | |
| PP&E (Gross) | $13.53B | $12.27B | $11.63B | $10.99B | $10.73B | $10.86B | $8.19B | $8.40B | $8.07B | $7.53B | $7.33B | $7.11B | |
| Accum. Depreciation | $7.90B | $7.13B | $6.65B | $6.05B | $5.62B | $5.61B | $5.23B | $5.51B | $5.27B | $4.92B | $4.77B | $4.62B | |
| Goodwill | $35.64B | $34.96B | $32.29B | $32.16B | $32.38B | $33.12B | $15.60B | $15.66B | $15.79B | $15.42B | $13.17B | $5.86B | |
| Intangibles | $52.64B | $60.07B | $55.61B | $67.44B | $75.95B | $82.88B | $18.65B | $21.23B | $27.56B | $28.90B | $19.71B | $1.51B | |
| Other Non-current Assets | $10.72B | $9.14B | $8.51B | $5.57B | $4.88B | $4.85B | $2.29B | $1.21B | $1.33B | $1.21B | $1.15B | $1.48B | |
| Total Assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B | |
| Accounts Payable | $34.73B | $2.94B | $3.69B | $2.93B | $2.88B | $2.28B | $1.45B | $1.55B | $1.47B | $1.41B | $1.60B | $1.40B | |
| Short-term Debt | $2.50B | $0 | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Current Liabilities | $43.29B | $38.75B | $37.84B | $29.54B | $35.19B | $28.66B | $15.59B | $17.24B | $16.64B | $9.78B | $10.89B | $11.39B | |
| Capital Leases | $689M | $697M | $735M | $754M | $713M | $832M | · | · | · | · | · | · | |
| Deferred Tax | $2.39B | $2.58B | $1.95B | $2.19B | $3.01B | $3.65B | $1.13B | $1.07B | $2.49B | $6.89B | $5.28B | $159M | |
| Other Non-current Liabilities | $32.57B | $30.13B | $32.33B | $30.66B | $28.70B | $27.61B | $17.60B | $1.31B | $1.24B | $1.16B | $844M | $990M | |
| Long-term Debt | $64.50B | $66.84B | $59.24B | $63.13B | $75.96B | $84.95B | $67.23B | · | · | · | · | · | |
| Total Debt | $2.50B | · | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Retained Earnings | $-15.49B | $-7.90B | $-1.00B | $4.78B | $3.13B | $1.05B | $4.72B | $3.37B | $5.46B | $4.38B | $2.25B | $535M | |
| Treasury Stock | $9.15B | $8.20B | $6.53B | $4.59B | $3.14B | $2.26B | $24.50B | $24.11B | $11.92B | $10.85B | $8.84B | $972M | |
| AOCI | $-1.14B | $-1.93B | $-2.31B | $-2.20B | $-2.90B | $-3.12B | $-3.60B | $-2.48B | $-2.73B | $-2.59B | $-2.56B | $-2.03B | |
| Stockholders' Equity | $-3.27B | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B | $-8.17B | $-8.45B | $5.10B | $4.64B | $3.94B | $1.74B | |
| Liabilities + Equity | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B |
Przepływy pieniężne 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $955M | $911M | $747M | $671M | $692M | $753M | $430M | $421M | $365M | $353M | $282M | $241M | |
| Deferred Tax | $-492M | $-1.45B | $-2.89B | $-1.93B | $-898M | $-2.33B | $122M | $-1.52B | $-4.16B | $-796M | $152M | $-380M | |
| Amort. of Intangibles | $7.38B | $7.62B | $7.95B | $7.69B | $7.72B | $5.80B | $1.55B | $1.29B | $1.08B | $764M | $419M | $403M | |
| Restructuring | · | · | · | · | · | · | $219M | $59M | $86M | $52M | $126M | $16M | |
| Operating Cash Flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B | $9.96B | $7.04B | $7.54B | $3.55B | |
| CapEx | $1.21B | $974M | $777M | $695M | $787M | $798M | $552M | $638M | $529M | $479M | $532M | $612M | |
| Investing Cash Flow | $-6.64B | $-20.82B | $-2.01B | $-623M | $-2.34B | $-37.56B | $596M | $-1.01B | $-274M | · | · | · | |
| Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Net Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Stock Repurchased | $980M | $1.71B | $1.97B | $1.49B | $934M | $978M | $629M | $12.01B | $1.41B | $6.03B | $7.59B | $665M | |
| Net Stock Activity | $-980M | $-1.71B | $-1.97B | $-1.49B | $-934M | $-978M | $-629M | $-12.01B | $-1.41B | $-6.03B | $-7.57B | $-652M | |
| Dividends Paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B | |
| Financing Cash Flow | $-12.72B | $-5.21B | $-17.22B | $-24.80B | $-19.04B | $-11.50B | $18.71B | $-14.40B | $-5.51B | $-3.93B | · | · | |
| Net Change in Cash | $-295M | $-7.29B | $3.61B | $-545M | $1.30B | $-31.48B | $32.63B | $-2.01B | $4.20B | $-3.30B | $51M | $-1.25B | |
| Taxes Paid | $3.63B | $4.10B | $4.70B | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B | $9.43B | $6.56B | $7.00B | $2.94B | |
| Levered FCF | $15.96B | $14.59B | $20.33B | $22.29B | $19.84B | $13.45B | $11.10B | $11.31B | $8.64B | $5.77B | $6.45B | $2.62B |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| Net Margin | 6.9% | 7.6% | 8.9% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | · | · | |
| Pretax Margin | 10.8% | 6.6% | 11.5% | 23.2% | 23.1% | 7.4% | 25.3% | 15.9% | 27.4% | 30.8% | 29.1% | 11.9% | |
| EBITDA Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| ROA | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% | · | · | |
| ROE | 15367.3% | 62.5% | 35.2% | 72.5% | 81.0% | 188.2% | -94.2% | -100.1% | 109.1% | 138.8% | · | · | |
| ROIC | -1254.6% | 317.0% | 96.0% | 92.3% | 103.3% | 117.9% | -148.6% | -147.1% | 119.9% | 141.3% | 134.1% | 117.9% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 | 0.8 | 3.2 | 1.0 | 1.3 | 1.7 | 1.5 | 1.4 | |
| Quick Ratio | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 | 0.6 | 2.9 | 0.8 | 0.6 | 0.7 | 0.8 | 0.7 | |
| Debt / Equity | -0.8 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.4 | 0.1 | 0.1 | 0.1 | 0.2 | |
| Interest Coverage | 5.2 | 3.3 | 5.7 | 8.1 | 7.4 | 4.6 | 7.3 | 4.7 | 8.3 | 9.0 | 10.5 | 8.0 |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 0.7 | |
| Inventory Turnover | 4.0 | 4.1 | 5.3 | 5.2 | 5.4 | 6.0 | 4.4 | 4.8 | 4.6 | 3.7 | 3.2 | 3.9 | |
| Receivables Turnover | 5.2 | 5.1 | 4.8 | 5.5 | 6.0 | 6.4 | 6.2 | 6.3 | · | · | · | · |
Stopy Wzrostu 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.6% | 3.7% | -6.4% | 3.3% | 22.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.8% | 0.08% | 5.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.3% | -12.1% | -59.0% | 2.8% | 137.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -29.1% | -28.2% | 0.00% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -2.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.2% | -12.0% | -58.9% | 2.5% | 150.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -29.1% | -28.2% | 1.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 8.6% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 6
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Net Income TTM | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| P/E | 96.8 | 74.4 | 57.0 | 24.4 | 21.0 | 39.4 | 16.8 | 25.2 | 29.3 | 17.3 | 18.9 | 59.5 | |
| Earnings Yield | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% | 5.3% | 1.7% | |
| Payout Ratio | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% | · | · | |
| Annual Payout | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B |
Rachunek zysków i strat 17
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B | $14.46B | $12.31B | $14.30B | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | |
| Cost of Revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B | $4.20B | $4.09B | $5.70B | $6.49B | $4.24B | $3.99B | $4.17B | $5.02B | |
| Gross Profit | · | · | $12.07B | · | · | · | $10.71B | · | · | · | $8.60B | · | · | · | $10.95B | · | |
| SG&A Expense | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.85B | $4.21B | $3.38B | $3.31B | $3.19B | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | |
| Operating Expenses | $10.56B | $11.01B | $12.07B | $13.87B | $10.53B | $9.61B | $16.59B | $10.63B | $10.46B | $9.51B | $11.11B | $11.65B | $9.35B | $9.46B | $9.62B | $10.21B | |
| Operating Income | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | $-1.49B | $3.83B | $4.00B | $2.80B | $3.19B | $2.28B | $4.51B | $2.77B | $5.50B | $4.60B | |
| Interest Expense | $746M | $717M | $714M | $739M | $740M | $700M | $702M | $720M | $726M | $660M | $564M | $555M | $552M | $553M | $566M | $560M | |
| Interest Income | $67M | $72M | · | $72M | $62M | $73M | · | $129M | $220M | $207M | · | $157M | $98M | $99M | · | $63M | |
| Other Non-op | $-1.48B | $-2.31B | $-1.21B | $-503M | $-2.66B | $-1.45B | $-150M | $-1.16B | $-1.34B | $-586M | $-1.56B | $95M | $-1.41B | $-1.80B | $-2.02B | $330M | |
| Pretax Income | $4.28B | $1.04B | $2.67B | $714M | $1.55B | $1.66B | $-2.27B | $2.08B | $2.15B | $1.75B | $1.21B | $1.95B | $2.61B | $475M | $2.96B | $4.40B | |
| Income Tax | $662M | $342M | $853M | $526M | $613M | $372M | $-2.25B | $520M | $773M | $383M | $388M | $172M | $583M | $234M | $493M | $448M | |
| Net Income | $3.61B | $695M | $1.82B | $186M | $938M | $1.29B | $-22M | $1.56B | $1.37B | $1.37B | $822M | $1.78B | $2.02B | $239M | $2.47B | $3.95B | |
| EPS (Basic) | $2.04 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.02 | $0.88 | $0.77 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.39 | $2.22 | |
| EPS (Diluted) | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.03 | $0.88 | $0.77 | $0.77 | $0.45 | $1.00 | $1.14 | $0.13 | $1.40 | $2.21 | |
| Shares (Basic) | 1,769,000,000 | 1,770,000,000 | -3,536,000,000 | 1,769,000,000 | 1,768,000,000 | 1,768,000,000 | -3,537,000,000 | 1,769,000,000 | 1,768,000,000 | 1,769,000,000 | -3,536,000,000 | 1,767,000,000 | 1,767,000,000 | 1,770,000,000 | -3,541,000,000 | 1,771,000,000 | |
| Shares (Diluted) | 1,771,000,000 | 1,774,000,000 | -3,542,000,000 | 1,772,000,000 | 1,771,000,000 | 1,772,000,000 | -3,543,000,000 | 1,772,000,000 | 1,771,000,000 | 1,773,000,000 | -3,545,000,000 | 1,771,000,000 | 1,771,000,000 | 1,776,000,000 | -3,552,000,000 | 1,776,000,000 | |
| EBITDA | $6.43B | $3.99B | · | $1.90B | $4.89B | $3.73B | · | $3.83B | $4.00B | $2.80B | · | $2.28B | $4.51B | $2.77B | · | $4.60B |
Bilans 26
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B | $18.07B | · | $13.29B | $8.76B | $6.71B | · | $11.83B | |
| Short-term Investments | · | · | $28M | $42M | $0 | $1M | $31M | $28M | $27M | $2M | · | $3M | $7M | $11M | · | $47M | |
| Receivables | $13.82B | $12.48B | $12.59B | $12.77B | $12.64B | $12.48B | $10.92B | $11.47B | $11.72B | $11.95B | · | $11.41B | $11.49B | $11.47B | · | $10.74B | |
| Inventory | $5.13B | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B | $4.45B | $4.22B | $4.25B | · | $3.98B | $4.05B | $3.83B | · | $3.17B | |
| Prepaid Expense | $8.15B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $33.67B | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B | $27.79B | $33.82B | $38.87B | · | $33.22B | $28.85B | $26.49B | · | $30.36B | |
| PP&E (Net) | $5.80B | $5.69B | $5.63B | $5.48B | $5.28B | $5.24B | $5.13B | $5.14B | $5.02B | $4.98B | · | $4.93B | $4.94B | $4.93B | · | $4.89B | |
| PP&E (Gross) | $13.96B | $13.73B | $13.53B | $13.23B | $12.93B | $12.57B | $12.27B | $12.28B | $11.90B | $11.72B | · | $11.37B | $11.32B | $11.14B | · | $10.68B | |
| Accum. Depreciation | $8.16B | $8.04B | $7.90B | $7.75B | $7.65B | $7.33B | $7.13B | $7.14B | $6.88B | $6.75B | · | $6.44B | $6.38B | $6.21B | · | $5.79B | |
| Goodwill | $35.52B | $35.57B | $35.64B | $35.63B | $35.64B | $35.28B | $34.96B | $35.30B | $33.39B | $33.43B | $32.29B | $32.09B | $32.22B | $32.22B | $32.16B | $31.73B | |
| Intangibles | $49.14B | $50.87B | $52.64B | $54.31B | $57.03B | $58.49B | $60.07B | $66.65B | $60.24B | $62.23B | · | $58.60B | $62.86B | $64.85B | · | $68.72B | |
| Other Non-current Assets | $10.73B | $10.54B | $10.72B | $9.64B | $9.66B | $9.19B | $9.14B | $8.29B | $9.20B | $9.07B | · | $7.09B | $6.20B | $5.80B | · | $5.38B | |
| Total Assets | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B | |
| Accounts Payable | $33.30B | $33.77B | $3.59B | $33.62B | $32.24B | $31.04B | $2.94B | $30.49B | $29.33B | $31.33B | · | $29.66B | $27.04B | $24.79B | · | $23.50B | |
| Short-term Debt | $0 | $0 | $2.50B | $3.79B | $5.56B | $1.59B | $0 | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Current Liabilities | $41.64B | $42.10B | $43.29B | $39.39B | $39.77B | $36.40B | $38.75B | $43.06B | $41.91B | $41.52B | · | $34.77B | $32.24B | $27.59B | · | $32.71B | |
| Capital Leases | · | · | $689M | · | · | · | $697M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | $2.28B | $2.33B | $2.39B | $2.48B | $2.55B | $2.58B | $2.58B | $2.75B | $2.73B | $2.72B | · | $2.04B | $2.12B | $2.11B | · | $1.97B | |
| Other Non-current Liabilities | $34.60B | $34.11B | $32.57B | $31.66B | $32.04B | $31.19B | $30.13B | $33.03B | $32.43B | $32.78B | · | $31.64B | $32.29B | $32.25B | · | $30.21B | |
| Long-term Debt | · | · | $64.50B | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $0 | $0 | · | $3.79B | $5.56B | $1.59B | · | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Retained Earnings | $-17.33B | $-17.87B | $-15.49B | $-14.23B | $-11.50B | $-9.53B | $-7.90B | $-4.96B | $-3.77B | $-2.38B | · | $933M | $1.79B | $2.39B | · | $4.95B | |
| Treasury Stock | $10.62B | $10.61B | $9.15B | $9.14B | $9.15B | $9.14B | $8.20B | $7.85B | $7.84B | $7.83B | · | $6.53B | $6.53B | $6.52B | · | $4.59B | |
| AOCI | $-1.16B | $-1.15B | $-1.14B | $-1.57B | $-1.54B | $-1.74B | $-1.93B | $-2.33B | $-2.51B | $-2.45B | · | $-2.35B | $-2.25B | $-2.23B | · | $-3.44B | |
| Stockholders' Equity | $-5.93B | $-6.66B | $-3.27B | $-2.64B | $-183M | $1.42B | $3.33B | $6.03B | $6.78B | $8.01B | · | $12.09B | $12.87B | $13.27B | · | $15.99B | |
| Liabilities + Equity | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B |
Przepływy pieniężne 15
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $166M | $444M | $157M | $209M | $179M | $410M | $164M | $181M | $218M | $348M | $125M | $130M | $179M | $313M | $132M | $126M | |
| Deferred Tax | $-195M | $137M | $-385M | $193M | $-272M | $-28M | $-767M | $-277M | $-16M | $-389M | $-1.39B | $-863M | $-368M | $-267M | $-516M | $-621M | |
| Amort. of Intangibles | $1.70B | $1.75B | $1.72B | $1.90B | $1.90B | $1.86B | $1.93B | $1.90B | $1.90B | $1.89B | $1.90B | $2.00B | $2.10B | $1.95B | $2.03B | $2.00B | |
| Operating Cash Flow | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B | $7.05B | $5.45B | $2.27B | $4.04B | $4.75B | $7.57B | $6.32B | $4.19B | $7.43B | $7.60B | |
| CapEx | $322M | $265M | $329M | $381M | $269M | $235M | $291M | $249M | $241M | $193M | $205M | $219M | $178M | $175M | $213M | $177M | |
| Investing Cash Flow | $-1.20B | $-574M | $-1.46B | $-3.26B | $-1.18B | $-735M | $-1.87B | $-8.26B | $-1.10B | $-9.59B | $-800M | $-369M | $-341M | $-499M | $-448M | $1.29B | |
| Debt Issued | $0 | $7.99B | $0 | $0 | $0 | $3.99B | $2.00B | $0 | $0 | $14.96B | · | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | $7.99B | · | · | · | $3.99B | · | · | · | $14.96B | · | · | · | $0 | · | · | |
| Stock Repurchased | $9M | $1.49B | $3M | $4M | $12M | $961M | $358M | $17M | $9M | $1.32B | $3M | $4M | $10M | $1.96B | $4M | $4M | |
| Net Stock Activity | · | $-1.49B | · | · | · | $-961M | · | · | · | $-1.32B | · | · | · | $-1.96B | · | · | |
| Dividends Paid | $3.07B | $3.09B | $2.91B | $2.91B | $2.91B | $2.92B | $2.75B | $2.75B | $2.75B | $2.77B | $2.63B | $2.63B | $2.62B | $2.66B | $2.51B | $2.50B | |
| Financing Cash Flow | $-5.05B | $919M | $-4.17B | $-4.59B | $-2.71B | $-1.26B | $-6.86B | $-3.07B | $-6.10B | $10.82B | $-4.45B | $-2.66B | $-3.92B | $-6.19B | $-9.63B | $-5.52B | |
| Net Change in Cash | $-2.82B | $4.16B | $-400M | $-838M | $1.29B | $-349M | $-1.73B | $-5.87B | $-4.94B | $5.25B | $-473M | $4.53B | $2.05B | $-2.49B | $-2.63B | $3.31B | |
| Free Cash Flow | · | $3.56B | · | · | · | $1.40B | · | · | · | $3.85B | · | · | · | $4.02B | · | · | |
| Levered FCF | · | $3.08B | · | · | · | $857M | · | · | · | $3.33B | · | · | · | $3.74B | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| Net Margin | 21.3% | 4.6% | · | 1.2% | 6.1% | 9.6% | · | 10.8% | 9.5% | 11.1% | · | 12.8% | 14.6% | 2.0% | · | 26.7% | |
| Pretax Margin | 25.2% | 6.9% | · | 4.5% | 10.1% | 12.4% | · | 14.4% | 14.8% | 14.3% | · | 14.0% | 18.8% | 3.9% | · | 29.7% | |
| EBITDA Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| ROA | 2.6% | 0.51% | · | 0.13% | 0.67% | 0.90% | · | 1.1% | 0.99% | 0.97% | · | 1.3% | 1.5% | 0.17% | · | 2.7% | |
| ROE | -118.1% | -26.6% | · | 11.0% | 28.4% | 27.3% | · | 17.2% | 14.0% | 12.9% | · | 12.7% | 14.7% | 1.6% | · | 26.7% | |
| ROIC | -91.6% | -40.2% | · | 43.7% | 55.2% | 96.2% | · | 47.7% | 37.7% | 27.3% | · | 17.2% | 27.2% | 10.6% | · | 25.8% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 0.8 | · | 0.7 | 0.7 | 0.8 | · | 0.6 | 0.8 | 0.9 | · | 1.0 | 0.9 | 1.0 | · | 0.9 | |
| Quick Ratio | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.4 | 0.6 | 0.7 | · | 0.7 | 0.6 | 0.7 | · | 0.7 | |
| Debt / Equity | 0.0 | 0.0 | · | -1.4 | -30.4 | 1.1 | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | 8.6 | 5.6 | · | 2.6 | 6.6 | 5.3 | · | 5.3 | 5.5 | 4.2 | · | 4.1 | 8.2 | 5.0 | · | 8.2 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.9 | 0.9 | · | 1.1 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.8 | 1.1 | 1.1 | · | 1.6 | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.5 |
Wycena (TTM) 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $64.39B | $62.82B | · | $59.64B | $58.33B | $57.37B | · | $55.53B | $55.00B | $54.40B | · | $55.14B | $56.02B | $56.74B | · | $57.82B | |
| Net Income TTM | $6.31B | $3.63B | · | $2.39B | $3.76B | $4.20B | · | $5.12B | $5.34B | $5.99B | · | $6.51B | $8.69B | $7.58B | · | $13.41B | |
| P/E | 71.1 | 107.1 | · | 175.4 | 88.4 | 89.2 | · | 68.6 | 57.2 | 54.0 | · | 40.8 | 27.7 | 37.7 | · | 17.9 | |
| Earnings Yield | 1.4% | 0.93% | · | 0.57% | 1.1% | 1.1% | · | 1.5% | 1.8% | 1.8% | · | 2.5% | 3.6% | 2.6% | · | 5.6% | |
| Payout Ratio | · | 444.0% | · | · | · | 227.5% | · | · | · | 202.5% | · | · | · | 1113.4% | · | · |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Marża Operacyjna % | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| Zysk netto | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| Rozwodniony EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | -0.8 | — | 0.0 | 0.0 | 0.0 |
| Wskaźnik bieżący | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 |
| Wskaźnik Szybkości | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
- Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
- How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
- AbbVie już jest Królem Dywidend. Oto dlaczego umowa z Apogee warta 10,9 mld USD może uczynić ją Dynastią
- AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
- AbbVie (ABBV) to Acquire Apogee Therapeutics
- Is AbbVie a Buy After Its Purchase of Apogee?
- Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
- AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
- Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger
- The $11 Billion Reason Abbvie Stock Is Up Today
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 4 559 emitentów · $203.7B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 248 (+10 vs poprzedni kw.) | 102 (-73 vs poprzedni kw.) | 1 873 (+177 vs poprzedni kw.) | 1 507 (-178 vs poprzedni kw.) | +62.9M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $29 038 274 101 | 115 396 098 | 14,25% | Akcje |
| STATE STREET CORP | $20 784 645 667 | 82 596 748 | 10,20% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12 199 002 913 | 48 477 996 | 5,99% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $10 348 337 446 | 41 208 853 | 5,08% | Akcje |
| Capital Research Global Investors | $7 574 798 407 | 30 101 551 | 3,72% | Akcje |
| NORGES BANK | $6 430 543 942 | 25 554 538 | 3,16% | Akcje |
| Capital World Investors | $4 826 436 854 | 19 178 966 | 2,37% | Akcje |
| Capital International Investors | $3 936 357 038 | 15 638 631 | 1,93% | Akcje |
| FMR LLC | $3 669 614 638 | 14 582 795 | 1,80% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3 235 535 863 | 12 854 734 | 1,59% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $2 501 249 007 | 9 939 791 | 1,23% | Akcje |
| Fisher Asset Management, LLC | $2 390 069 445 | 9 497 970 | 1,17% | Akcje |
| VANGUARD GROUP INC | $2 321 825 812 | 10 161 608 | 1,14% | Akcje |
| AMERIPRISE FINANCIAL INC | $2 300 268 904 | 9 140 996 | 1,13% | Akcje |
| UBS Group AG | $1 821 262 870 | 7 237 573 | 0,89% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $1 804 931 470 | 7 172 673 | 0,89% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $1 626 458 497 | 6 463 432 | 0,80% | Akcje |
| BANK OF AMERICA CORP /DE/ | $1 288 677 353 | 5 121 115 | 0,63% | Akcje |
| BlackRock, Inc. | $1 281 498 844 | 5 092 588 | 0,63% | Akcje |
| Swiss National Bank | $1 255 358 984 | 4 988 710 | 0,62% | Akcje |
| GOLDMAN SACHS GROUP INC | $1 238 268 174 | 4 920 792 | 0,61% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $1 229 678 938 | 4 886 670 | 0,60% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $1 194 403 724 | 4 746 478 | 0,59% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1 092 298 708 | 4 340 720 | 0,54% | Akcje |
| LPL Financial LLC | $1 030 798 580 | 4 096 323 | 0,51% | Akcje |
| National Pension Service | $1 008 968 950 | 4 009 573 | 0,50% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $1 005 413 025 | 3 995 442 | 0,49% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $992 857 195 | 3 945 546 | 0,49% | Akcje |
| Vanguard Global Advisers, LLC | $963 609 833 | 3 829 319 | 0,47% | Akcje |
| Robeco Institutional Asset Management B.V. | $897 126 545 | 3 565 119 | 0,44% | Akcje |
| Legal & General Group Plc | $895 484 594 | 3 558 594 | 0,44% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $890 041 939 | 4 092 335 | 0,44% | Akcje |
| California Public Employees Retirement System | $862 671 241 | 3 428 196 | 0,42% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $817 473 174 | 3 248 582 | 0,40% | Akcje |
| CITADEL ADVISORS LLC | $797 644 194 | 3 169 783 | 0,39% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $768 828 394 | 3 055 271 | 0,38% | Akcje |
| BARCLAYS PLC | $739 133 865 | 2 937 267 | 0,36% | Akcje |
| NORDEA INVESTMENT MANAGEMENT AB | $721 397 794 | 2 869 636 | 0,35% | Akcje |
| RHUMBLINE ADVISERS | $687 895 224 | 2 733 648 | 0,34% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $667 358 842 | 2 652 038 | 0,33% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $655 267 540 | 2 603 988 | 0,32% | Akcje |
| TD Asset Management Inc | $648 811 716 | 2 578 333 | 0,32% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $631 733 198 | 2 904 654 | 0,31% | Akcje |
| PNC Financial Services Group, Inc. | $625 922 542 | 2 487 373 | 0,31% | Akcje |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $584 076 068 | 2 321 078 | 0,29% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $582 914 088 | 2 680 188 | 0,29% | Akcje |
| FIFTH THIRD BANCORP | $541 376 862 | 2 151 394 | 0,27% | Akcje |
| Assenagon Asset Management S.A. | $527 911 026 | 2 097 882 | 0,26% | Akcje |
| JANE STREET GROUP, LLC | $520 089 552 | 2 066 800 | 0,26% | Opcja kupna |
| CITADEL ADVISORS LLC | $500 839 092 | 1 990 300 | 0,25% | Opcja kupna |
| JANE STREET GROUP, LLC | $499 555 728 | 1 985 200 | 0,25% | Opcja sprzedaży |
| HighTower Advisors, LLC | $495 062 218 | 1 967 343 | 0,24% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $485 540 135 | 1 929 503 | 0,24% | Akcje |
| GQG Partners LLC | $483 559 978 | 1 921 614 | 0,24% | Akcje |
| PRUDENTIAL FINANCIAL INC | $478 733 776 | 1 902 455 | 0,23% | Akcje |
| Fayez Sarofim & Co | $464 570 323 | 1 846 170 | 0,23% | Akcje |
| CAPTRUST FINANCIAL ADVISORS | $457 328 195 | 1 817 391 | 0,22% | Akcje |
| US BANCORP \DE\ | $431 161 990 | 1 713 408 | 0,21% | Akcje |
| MACKENZIE FINANCIAL CORP | $429 747 269 | 1 707 786 | 0,21% | Akcje |
| AVIVA PLC | $418 894 036 | 1 664 656 | 0,21% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $417 685 426 | 1 659 851 | 0,21% | Akcje |
| Caisse de depot et placement du Quebec | $413 100 025 | 1 641 631 | 0,20% | Akcje |
| Baird Financial Group, Inc. | $408 320 931 | 1 622 639 | 0,20% | Akcje |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $402 263 652 | 1 598 568 | 0,20% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $398 029 187 | 1 581 740 | 0,20% | Akcje |
| Eurizon Capital SGR S.p.A. | $382 266 246 | 1 515 159 | 0,19% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $381 605 769 | 1 516 475 | 0,19% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $379 803 020 | 1 509 311 | 0,19% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $358 269 921 | 1 448 017 | 0,18% | Akcje |
| APG Asset Management N.V. | $355 105 573 | 1 613 385 | 0,17% | Akcje |
| CINCINNATI INSURANCE CO | $353 604 528 | 1 405 200 | 0,17% | Akcje |
| CITADEL ADVISORS LLC | $352 698 624 | 1 401 600 | 0,17% | Opcja sprzedaży |
| Alecta Tjanstepension Omsesidigt | $350 097 440 | 1 393 700 | 0,17% | Akcje |
| UBS Group AG | $347 253 386 | 1 379 961 | 0,17% | Opcja kupna |
| ROYAL LONDON ASSET MANAGEMENT LTD | $337 822 422 | 1 342 483 | 0,17% | Akcje |
| Korea Investment CORP | $324 892 907 | 1 291 102 | 0,16% | Akcje |
| BLAIR WILLIAM & CO/IL | $324 076 456 | 1 287 857 | 0,16% | Akcje |
| CIBC Bancorp USA Inc. | $319 137 398 | 1 268 149 | 0,16% | Akcje |
| NEUBERGER BERMAN GROUP LLC | $312 155 419 | 1 240 484 | 0,15% | Akcje |
| KEYBANK NATIONAL ASSOCIATION/OH | $297 253 749 | 1 181 266 | 0,15% | Akcje |
| PFA Pension, Forsikringsaktieselskab | $296 007 110 | 1 176 312 | 0,15% | Akcje |
| Candriam S.C.A. | $292 814 436 | 1 164 745 | 0,14% | Akcje |
| BANK OF MONTREAL /CAN/ | $287 298 646 | 1 141 705 | 0,14% | Akcje |
| MENORA MIVTACHIM HOLDINGS LTD. | $286 660 236 | 1 139 168 | 0,14% | Akcje |
| Quantinno Capital Management LP | $286 551 564 | 1 138 736 | 0,14% | Akcje |
| CITIGROUP INC | $284 177 052 | 1 129 300 | 0,14% | Opcja sprzedaży |
| D. E. Shaw & Co., Inc. | $279 166 396 | 1 109 388 | 0,14% | Akcje |
| Nuveen, LLC | $278 124 451 | 1 105 247 | 0,14% | Akcje |
| Public Sector Pension Investment Board | $273 989 658 | 1 088 816 | 0,13% | Akcje |
| STOREBRAND ASSET MANAGEMENT AS | $271 386 191 | 1 078 470 | 0,13% | Akcje |
| ProShare Advisors LLC | $270 105 595 | 1 073 381 | 0,13% | Akcje |
| Aberdeen Group plc | $269 639 809 | 1 071 530 | 0,13% | Akcje |
| Guinness Asset Management LTD | $261 219 378 | 1 042 337 | 0,13% | Akcje |
| TRUIST FINANCIAL CORP | $259 417 636 | 1 030 908 | 0,13% | Akcje |
| Cerity Partners LLC | $251 309 055 | 998 667 | 0,12% | Akcje |
| Cetera Investment Advisers | $249 297 571 | 990 692 | 0,12% | Akcje |
| JONES FINANCIAL COMPANIES LLLP | $246 700 034 | 973 752 | 0,12% | Akcje |
| COMMONWEALTH EQUITY SERVICES, LLC | $245 375 470 | 975 105 | 0,12% | Akcje |
| FEDERATED HERMES, INC. | $244 359 552 | 971 068 | 0,12% | Akcje |
| SATURNA CAPITAL CORP | $240 562 538 | 958 069 | 0,12% | Akcje |
Insiderzy spółki 38 insiderów · 20 dyrektorzy generalni · 15 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Robert A. Michael | CHIEF EXECUTIVE OFFICER | 28 lutego 2025 F | 132 821 | 0 | 0 | $0 |
| Scott T Reents | EVP, CHIEF FINANCIAL OFFICER | 14 marca 2025 S | 11 577 | 0 | 0 | $0 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | 14 sierpnia 2026 M | 74 430 | 0 | 1 | $-8 177 500 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | 12 sierpnia 2025 M | 177 292 | 0 | 0 | $0 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | 31 marca 2025 M | 53 234 | 0 | 0 | $0 |
| Perry C Siatis | EVP, GC AND SECRETARY | 3 marca 2025 D | 4 619 | 0 | 0 | $0 |
| Timothy J. Richmond | EVP, CHIEF HR OFFICER | 3 marca 2025 S | 6 130 | 0 | 0 | $0 |
| Roopal Thakkar | EVP, R&D and CSO | 28 lutego 2025 F | 42 276 | 0 | 0 | $0 |
| Kevin K Buckbee | SVP, CONTROLLER | 28 lutego 2025 F | 7 797 | 0 | 0 | $0 |
| Thomas J Hudson | SVP, CSO, GLOBAL RESEARCH | 28 lutego 2024 F | 107 267 | 0 | 0 | $0 |
| Carrie C Strom | SVP & PRES GLOBAL ALLERG AESTH | 11 maja 2023 F | 28 024 | 0 | 0 | $0 |
| Elaine K. Sorg | SVP, US COMMERCIAL OPERATIONS | 25 kwietnia 2023 M | 35 330 | 0 | 0 | $0 |
| Brian L Durkin | VP, CONTROLLER | 28 lutego 2023 F | 33 149 | 0 | 0 | $0 |
| Michael Severino | Vice Chairman | 23 maja 2022 M | 152 103 | 0 | 0 | $0 |
| Henry O Gosebruch | EVP, Chief Strategy Officer | 16 maja 2022 M | 41 623 | 0 | 0 | $0 |
| Laura J Schumacher | Vice Chairman | 25 lutego 2022 F | 248 002 | 0 | 0 | $0 |
| Carlos Alban | Vice Chairman | 16 listopada 2020 M | 114 899 | 0 | 0 | $0 |
| William J Chase | EVP, Finance & Administration | 26 czerwca 2019 P | 169 552 | 0 | 0 | $0 |
| Thomas A. Hurwich | VP, Controller | 28 lutego 2017 F | 62 329 | 0 | 0 | $0 |
| John M. Leonard | SVP, Chief Scientific Officer | 15 marca 2013 M | 107 320 | 0 | 0 | $0 |
| Susan E Quaggin | Dyrektor | 30 czerwca 2026 A | 2 525 | 0 | 0 | $0 |
| Edward J Rapp | Dyrektor | 30 czerwca 2026 A | 45 964 | 0 | 0 | $0 |
| Frederick H Waddell | Dyrektor | 8 maja 2026 A | 30 076 | 0 | 0 | $0 |
| Thomas J Falk | Dyrektor | 8 maja 2026 A | 2 321 | 0 | 0 | $0 |
| Roxanne S Austin | Dyrektor | 8 maja 2026 A | 39 576 | 0 | 0 | $0 |
| Robert J Alpern | Dyrektor | 30 czerwca 2025 A | 35 646 | 0 | 0 | $0 |
| Jennifer L. Davis | Dyrektor | 9 maja 2025 A | 2 525 | 0 | 0 | $0 |
| Melody B Meyer | Dyrektor | 9 maja 2025 A | 16 498 | 0 | 0 | $0 |
| William H.L. Burnside | Dyrektor | 9 maja 2025 A | 26 958 | 0 | 0 | $0 |
| Brett J Hart | Dyrektor | 9 maja 2025 A | 19 472 | 0 | 0 | $0 |
| Glenn F Tilton | Dyrektor | 9 maja 2025 A | 51 564 | 0 | 0 | $0 |
| Richard A Gonzalez | Dyrektor | 31 marca 2025 G | 386 479 | 0 | 0 | $0 |
| Edward M Liddy | Dyrektor | 31 marca 2022 A | 26 683 | 0 | 0 | $0 |
| Roy S Roberts | Dyrektor | 8 maja 2015 A | 27 486 | 0 | 0 | $0 |
| AbbVie Inc. | Posiadacz 10% | 28 marca 2017 S | 1 190 473 | 0 | 0 | $0 |
| ABBOTT LABORATORIES | Posiadacz 10% | 12 grudnia 2012 J | 0 | 0 | 0 | $0 |
| Rebecca B Roberts | — | 8 maja 2026 A | 14 846 | 0 | 0 | $0 |
| Thomas C Freyman | — | 8 maja 2026 A | 127 869 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 1 akcja
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| AbbVie Inc. | 6 października 2017 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 301 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 7,39% | 10 640 NS | 30 czerwca 2026 | N-PORT |
| IYH · iShares Trust | 7,16% | 1 056 138 SH | 21 sierpnia 2026 | Dziennie |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 6,58% | 3 464 NS | 30 kwietnia 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 6,56% | 5 317 086 SH | 19 sierpnia 2026 | Dziennie |
| HDV · iShares Trust | 6,21% | 3 641 083 SH | 21 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 6,03% | 814 750 NS | 30 kwietnia 2026 | N-PORT |
| RXL · ProShares Trust | 5,57% | 18 435 NS | 31 maja 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 5,39% | 35 243 NS | 30 kwietnia 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 5,39% | 108 712 SH | 21 sierpnia 2026 | Dziennie |
| IXJ · iShares Trust | 4,97% | 825 161 SH | 21 sierpnia 2026 | Dziennie |
| MEDI · Harbor ETF Trust | 4,78% | 6 235 NS | 30 kwietnia 2026 | N-PORT |
| LCOW · Pacer Funds Trust | 4,28% | 4 651 NS | 30 kwietnia 2026 | N-PORT |
| FLAG · Global X Funds | 4,27% | 333 NS | 30 kwietnia 2026 | N-PORT |
| PSIL · AdvisorShares Trust | 4,14% | 7 318 NS | 30 czerwca 2026 | N-PORT |
| FDV · Federated Hermes ETF Trust | 3,86% | 136 965 NS | 30 kwietnia 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 3,73% | 264 051 SH | 21 sierpnia 2026 | Dziennie |
| DIVL · Madison ETFs Trust | 3,68% | 8 786 NS | 30 czerwca 2026 | N-PORT |
| USMC · Principal Exchange-Traded Funds | 3,39% | 470 441 NS | 30 czerwca 2026 | N-PORT |
| AGNG · Global X Funds | 3,16% | 11 869 NS | 31 maja 2026 | N-PORT |
| DGRO · iShares Trust | 3,04% | 5 059 458 SH | 21 sierpnia 2026 | Dziennie |
| ABOT · Abacus FCF ETF Trust | 2,85% | 594 NS | 30 kwietnia 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,81% | 22 700 NS | 31 maja 2026 | N-PORT |
| PAYR · Federated Hermes ETF Trust | 2,69% | 4 656 NS | 30 kwietnia 2026 | N-PORT |
| QDEF · FlexShares Trust | 2,66% | 66 732 NS | 30 kwietnia 2026 | N-PORT |
| QDF · FlexShares Trust | 2,63% | 264 330 NS | 30 kwietnia 2026 | N-PORT |
| SNPV · DBX ETF Trust | 2,62% | 27 726 NS | 29 maja 2026 | N-PORT |
| BRIF · FIS Trust | 2,50% | 16 907 NS | 31 maja 2026 | N-PORT |
| ABFL · Abacus FCF ETF Trust | 2,48% | 58 404 NS | 30 kwietnia 2026 | N-PORT |
| XT · iShares Trust | 2,47% | 372 278 SH | 21 sierpnia 2026 | Dziennie |
| DIVY · Tidal Trust I | 2,42% | 3 163 NS | 31 maja 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,40% | 5 714 NS | 31 maja 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,35% | 498 NS | 30 kwietnia 2026 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 2,20% | 12 240 NS | 31 maja 2026 | N-PORT |
| VUSE · ETF Series Solutions | 2,15% | 67 918 NS | 31 maja 2026 | N-PORT |
| QLV · FlexShares Trust | 2,13% | 17 108 NS | 30 kwietnia 2026 | N-PORT |
| CGCV · Capital Group Conservative Equity E… | 2,13% | 171 487 NS | 31 maja 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 2,10% | 1 110 490 SH | 19 sierpnia 2026 | Dziennie |
| FDIV · EA Series Trust | 2,10% | 7 229 NS | 30 kwietnia 2026 | N-PORT |
| FLCG · Federated Hermes ETF Trust | 2,04% | 53 408 NS | 31 maja 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 2,03% | 19 271 NS | 30 czerwca 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 1,99% | 69 180 000 | 21 sierpnia 2026 | Dziennie |
| VIG · VANGUARD SPECIALIZED FUNDS | 1,94% | 9 981 469 SH | 19 sierpnia 2026 | Dziennie |
| PJFV · PGIM ETF Trust | 1,90% | 7 518 NS | 29 maja 2026 | N-PORT |
| SWP · Manager Directed Portfolios | 1,89% | 13 423 NS | 31 maja 2026 | N-PORT |
| CDEI · Morgan Stanley ETF Trust | 1,88% | 1 357 NS | 30 czerwca 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,87% | 4 006 NS | 30 kwietnia 2026 | N-PORT |
| SDOG · ALPS ETF Trust | 1,87% | 118 805 NS | 31 maja 2026 | N-PORT |
| ANEW · ProShares Trust | 1,86% | 661 NS | 31 maja 2026 | N-PORT |
| VYM · VANGUARD WHITEHALL FUNDS | 1,85% | 7 067 444 SH | 19 sierpnia 2026 | Dziennie |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 1,82% | 54 664 000 | 21 sierpnia 2026 | Dziennie |